Literature DB >> 25895932

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment.

Javier Pagonabarraga1, Jaime Kulisevsky2, Antonio P Strafella3, Paul Krack4.   

Abstract

Normal maintenance of human motivation depends on the integrity of subcortical structures that link the prefrontal cortex with the limbic system. Structural and functional disruption of different networks within these circuits alters the maintenance of spontaneous mental activity and the capacity of affected individuals to associate emotions with complex stimuli. The clinical manifestations of these changes include a continuum of abnormalities in goal-oriented behaviours known as apathy. Apathy is highly prevalent in Parkinson's disease (and across many neurodegenerative disorders) and can severely affect the quality of life of both patients and caregivers. Differentiation of apathy from depression, and discrimination of its cognitive, emotional, and auto-activation components could guide an individualised approach to the treatment of symptoms. The opportunity to manipulate dopaminergic treatment in Parkinson's disease allows researchers to study a continuous range of motivational states, from apathy to impulse control disorders. Parkinson's disease can thus be viewed as a model that provides insight into the neural substrates of apathy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25895932     DOI: 10.1016/S1474-4422(15)00019-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  105 in total

1.  Echinacoside Protects Against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation.

Authors:  Qing Zhao; Xiaoyan Yang; Dingfang Cai; Ling Ye; Yuqing Hou; Lijun Zhang; Jiwei Cheng; Yuan Shen; Kaizhe Wang; Yu Bai
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

2.  Apathy and its impact on patient outcome in amyotrophic lateral sclerosis.

Authors:  J Caga; S Hsieh; E Highton-Williamson; M C Zoing; E Ramsey; E Devenney; R M Ahmed; M C Kiernan
Journal:  J Neurol       Date:  2017-11-30       Impact factor: 4.849

3.  DRD2 Genotype-Based Variants Modulates D2 Receptor Distribution in Ventral Striatum.

Authors:  Mikaeel Valli; Sang Soo Cho; Mario Masellis; Robert Chen; Pablo Rusjan; Jinhee Kim; Yuko Koshimori; Alexander Mihaescu; Antonio P Strafella
Journal:  Mol Neurobiol       Date:  2019-03-08       Impact factor: 5.590

4.  Depressive symptoms precede cognitive impairment in de novo Parkinson's disease patients: Analysis of the PPMI cohort.

Authors:  Jacob D Jones; Natalie E Kurniadi; Taylor P Kuhn; Sarah M Szymkowicz; Joseph Bunch; Elizabeth Rahmani
Journal:  Neuropsychology       Date:  2019-07-25       Impact factor: 3.295

Review 5.  Inhibitory dysfunction contributes to some of the motor and non-motor symptoms of movement disorders and psychiatric disorders.

Authors:  Marjan Jahanshahi; John C Rothwell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-04-19       Impact factor: 6.237

6.  Cerebral blood flow in striatal regions is associated with apathy in patients with schizophrenia.

Authors:  Karoline Schneider; Lars Michels; Matthias N Hartmann-Riemer; Achim Burrer; Philippe N Tobler; Philipp Stämpfli; Matthias Kirschner; Erich Seifritz; Stefan Kaiser
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

Review 7.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

8.  Multidimensional model of apathy in older adults using partial least squares--path modeling.

Authors:  Stéphane Raffard; Catherine Bortolon; Marianna Burca; Marie-Christine Gely-Nargeot; Delphine Capdevielle
Journal:  Age (Dordr)       Date:  2016-05-06

9.  Variables associated with physical health-related quality of life in Parkinson's disease patients presenting for deep brain stimulation.

Authors:  Alexandre Paim Diaz; Fernando Cini Freitas; Maria Emília de Oliveira Thais; Fernando Zanela da Silva Areas; Marcelo Liborio Schwarzbold; Rodrigo Debona; Jean Costa Nunes; Ricardo Guarnieri; Daniel Martinez-Ramirez; Rui Daniel Prediger; Aparna Wagle Shukla; Marcelo Neves Linhares; Roger Walz
Journal:  Neurol Sci       Date:  2016-07-25       Impact factor: 3.307

Review 10.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.